Latest News
LTR Pharma launches Roxus nasal spray for ED in the US
15 October 2026 - Australian pharmaceutical company LTR Pharma Limited (ASX: LTP) on Thursday introduced Roxus, a prescription nasal spray for erectile dysfunction (ED), to patients across the United States.The product delivers vardenafil via the com...
Galderma reports sustained symptom improvements with nemolizumab in children with atopic dermatitis
15 October 2026 - Dermatology company Galderma (SIX:GALD) on Thursday announced Phase II study results showing that nemolizumab improved itch severity, sleep disturbance and quality of life in children aged 2 to 11 with moderate-to-severe atopic derm...
KDventures portfolio company Modus Therapeutics pauses Phase 2a trial enrolment, delays expected readout
15 October 2026 - KDventures AB (STO:KDV), a Nordic investment company focused on life sciences, disclosed on Thursday that portfolio company Modus Therapeutics has temporarily paused enrolment in Part 2 of its Phase 2a study evaluating sevuparin in ...
Philips-led EXIT-CVD consortium launches cardiovascular clinical studies across Europe
15 October 2026 - Dutch health technology company Royal Philips (NYSE:PHG) (AEX:PHIA) on Thursday announced the launch of EXIT-CVD, a five-year research initiative led by Philips and University Medical Center Groningen (UMCG) to advance how cardiovas...
SciBase technology selected as primary endpoint in NIH-led skin exposure study
15 October 2026 - Swedish medical technology company SciBase Holding AB (STO: SCIB), which develops AI-based dermatology assessment devices, said on Thursday it will participate in a new study led by the US National Institute of Health (NIH) in colla...